Edition:
United Kingdom

Novozymes A/S (NZYMb.CO)

NZYMb.CO on Copenhagen Stock Exchange

278.10DKK
16 Aug 2019
Change (% chg)

kr.5.50 (+2.02%)
Prev Close
kr.272.60
Open
kr.272.00
Day's High
kr.278.10
Day's Low
kr.271.90
Volume
510,874
Avg. Vol
567,317
52-wk High
kr.363.10
52-wk Low
kr.260.10

Latest Key Developments (Source: Significant Developments)

Lars Green Will Join Novozymes As EVP And CFO
Friday, 9 Aug 2019 

Aug 9 (Reuters) - Novozymes A/S ::REG-CHANGE TO THE BOARD OF DIRECTORS AND EXECUTIVE LEADERSHIP TEAM – APPOINTMENT OF EXECUTIVE VICE PRESIDENT AND CFO.LARS GREEN WILL JOIN NOVOZYMES A/S AS EVP AND CFO.THE CHANGES HAVE NO IMPACT ON THE FINANCIAL OUTLOOK FOR 2019..LARS GREEN HAS RESIGNED FROM THE BOARD OF DIRECTORS WITH IMMEDIATE EFFECT, INCLUDING AS CHAIRMAN OF THE AUDIT COMMITTEE.BOARD OF DIRECTORS ELECTED AGNETE RAASCHOU-NIELSEN AS NEW CHAIR OF AUDIT COMMITTEE WITH IMMEDIATE EFFECT.  Full Article

Novozymes Expects To Announce New CFO
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Novozymes A/S ::REG-CHANGE TO THE EXECUTIVE LEADERSHIP TEAM.A/S AND PRISCA HAVRANEK-KOSICEK HAVE MUTUALLY AGREED THAT SHE WILL DISCONTINUE HER POSITION AS EVP AND CFO WITH IMMEDIATE EFFECT..NOVOZYMES EXPECTS TO ANNOUNCE A NEW APPOINTMENT TO THE POSITION SOON..THE CHANGE HAS NO IMPACT ON THE FINANCIAL OUTLOOK FOR 2019.  Full Article

Novozymes Strategy Update For The Three-Year Period 2020-2022
Sunday, 16 Jun 2019 

June 16 (Reuters) - Novozymes A/S ::REG-STRATEGY UPDATE FOR THE THREE-YEAR PERIOD 2020-2022.ANNOUNCES STRATEGY UPDATE FOR THE THREE-YEAR PERIOD 2020-2022.2019 OUTLOOK FROM JUNE 6, 2019, IS MAINTAINED.IN 3-YEAR PERIOD 2020-2022, NOVOZYMES TARGETS 5+% ANNUAL ORGANIC SALES GROWTH WITH 2020 LIKELY NEGATIVELY IMPACTED BY PORTFOLIO CHANGES.THE 2019 OUTLOOK FROM JUNE 6, 2019, IS MAINTAINED.BY 2022, CO EXPECTS THE EBIT MARGIN TO BE AT 28% OR ABOVE AND ROIC INCL. GOODWILL AT 23% OR ABOVE.  Full Article

Novozymes Q1 EBIT DKK 1.02 Bln, In Line With Expectations
Wednesday, 24 Apr 2019 

April 24 (Reuters) - Novozymes A/S ::REG-INTERIM REPORT FOR THE FIRST 3 MONTHS OF 2019.FULL-YEAR EARNINGS OUTLOOK MAINTAINED AFTER EARLY-APRIL UPGRADE.Q1 TOTAL SALES DKK 3.52 BILLION (REUTERS POLL DKK 3.60 BILLION).NARROWED SALES GROWTH GUIDANCE FOLLOWING WEAKNESS IN US BIOETHANOL..Q1 NET PROFIT DOWN 14% Y/Y DUE TO LOWER EBIT AND HEDGING LOSSES.Q1 EBIT DKK 1.02 BILLION (REUTERS POLL DKK 1.02 BILLION).FLOODS IN THE MIDWEST HAVE MADE IT TOUGHER FOR OUR CUSTOMERS..IT WILL BE DIFFICULT TO REACH THE TOP END OF THE GUIDED ORGANIC SALES GROWTH RANGE, AND WE ADJUST OUR OUTLOOK TO 3-5%..SAYS MIDDLE EAST COMPARISON GETS EASIER.SALES TO THE HOUSEHOLD CARE INDUSTRY DECLINED BY 3% ORGANICALLY AND BY 2% IN DKK IN THE FIRST QUARTER OF 2019 COMPARED WITH THE FIRST QUARTER OF 2018.DEVELOPED MARKETS FLAT; 10% ORGANIC SALES DECLINE IN EMERGING MARKETS, WITH THE MIDDLE EAST AS THE MAIN DRAG.NEGATIVE IMPACT FROM THE MIDDLE EAST, FEED ENZYMES AND THE PLANNED PRICE REDUCTIONS IN US BAKING ENZYMES.FOOD & BEVERAGES SALES DECLINED BY 2% ORGANICALLY AND GREW BY 1% IN DKK IN THE FIRST QUARTER OF 2019 COMPARED WITH THE SAME PERIOD LAST YEAR.Q1 SALES TO BIOENERGY DECLINED BY 8% ORGANICALLY AND BY 4% IN DKK COMPARED WITH THE FIRST QUARTER OF 2018..STOCK BUYBACK PROGRAM OF UP TO DKK 2BN TO BE INITIATED APRIL 25, 2019..  Full Article

Novozymes to focus on peanuts with new BioAg structure - EVP
Friday, 5 Apr 2019 

April 5 (Reuters) - Novozymes NZYMB.CO::EVP SAYS NEW BIOAG STRUCTURE GIVES ROOM TO FOCUS ON OTHER CROPS THAN CORN AND SOY, SUCH AS PEANUTS.EVP SAYS WITH NEW BIOAG PARTNERSHIPS COMPANY IS QUITE CONFIDENT IN LONG-TERM GOAL OF SUPPLYING TECHNOLOGY TO 250-500 MILLION ACRES.EVP SAYS SEES NO REASON TO CHANGE WIDE RANGE LONG-TERM TARGET OF SUPPLYING TECHNOLOGY TO 250-500 MILLION ACRES EVEN THOUGH THE COMPANY EXPECTS TO INCREASE THE RETURN ON INVESTED CAPITAL IN BIOAG.  Full Article

Novozymes Co And BioAg Announce Continuation With Bayer As Core Partner
Thursday, 4 Apr 2019 

April 4 (Reuters) - Novozymes ::CO AND BIOAG ANNOUNCE CONTINUATION WITH BAYER AS CORE PARTNER.CO IS PURSUING A MULTI-PARTNER SETUP, WITH TWO NEW PARTNERS, UNIVAR SOLUTIONS AND UPL.THE 2019 ORGANIC SALES GROWTH OUTLOOK FOR NOVOZYMES AND FOR THE AG & FEED BUSINESS IS MAINTAINED.THE LONG-TERM BIOAG TARGET OF SUPPLYING TECHNOLOGY TO 250-500 MILLION ACRES IS ALSO MAINTAINED.EBIT MARGIN,NET PROFIT GROWTH,FREE CASH FLOW BEFORE ACQUISITIONS AND ROIC GUIDANCE FOR 2019 UPDATED DUE TO ONE-OFF DEFERRED INCOME RELEASE.THE EBIT MARGIN GUIDANCE FOR 2019 IS INCREASED FROM 28-29% TO 29-30%.THE ROIC GUIDANCE FOR 2019 IS INCREASED FROM ABOUT 23% TO ABOUT 24%.NET PROFIT GROWTH GUIDANCE FOR 2019 INCREASED FROM 0-5% TO 5-10%.  Full Article

Novozymes Q4 EBIT At DKK 1.06 Bln, In Line With Expectations
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Novozymes A/S ::REG-GROUP FINANCIAL STATEMENT FOR 2018.Q4 SALES DKK 3.71 BILLION (REUTERS POLL DKK 3.79 BILLION).Q4 EBIT DKK 1.06 BILLION (REUTERS POLL DKK 1.06 BILLION).PROPOSED 2018 DIVIDEND OF 5 DKK/SHARE. 11.1% GROWTH IN DIVIDEND. 44.6% PAYOUT RATIO.Q4 NET PROFIT DKK 837 MILLION (REUTERS POLL DKK 823 MILLION).2019 OUTLOOK: ORGANIC SALES GROWTH OF 3-6%, WITH AN ADDITION OF CA. 1 PERCENTAGE POINT FOR GROWTH IN DKK.SEES 2019 SALES GROWTH, ORGANIC 3-6%.FY DIVIDEND DKK 5 PER SHARE (REUTERS POLL DKK 4.77 PER SHARE).SEES 2019 EBIT MARGIN 28-29%.2019 OUTLOOK: EBIT MARGIN AT 28-29% SUPPORTED BY SOLID PRODUCTIVITY GAINS.SEES 2019 NET PROFIT GROWTH 0-5%.2019 OUTLOOK: NET PROFIT GROWTH OF 0-5%..SAYS NEW STOCK BUYBACK PROGRAM IN 2019.TO INITIATE A NEW STOCK BUYBACK PROGRAM FOR 2019 WORTH UP TO DKK 2 BILLION IN TOTAL OR A MAXIMUM OF 20 MILLION SHARES.2019 ROIC EXPECTED AT ABOUT 23% (ABOUT 24% EXCLUDING. IFRS 16 LEASES)..  Full Article

Novozymes CFO says still sees weak Middle East markets in 2019
Wednesday, 23 Jan 2019 

Jan 24 (Reuters) - NOVOZYMES A/S CHIEF FINANCIAL OFFICER PRISCA HAVRANEK-KOSICEK SAYS IN TELEPHONE INTERVIEW WITH REUTERS::TREND UNCHANGED IN THE MIDDLE EAST, THE DAMPENING FACTOR FROM THERE CONTINUES IN 2019.UNCERTAINTIES, PARTICULARLY IN THE MIDDLE EAST, ARE THE MAIN REASON FOR A WIDER GUIDANCE RANGE FOR 2019 THAN FOR 2018.THE UNDERLYING GROWTH IN EMERGING MARKETS WITHIN HOUSEHOLD CARE IS VERY, VERY GOOD AND IS EXPECTED TO CONTINUE.REGARDING THE E15 IN THE U.S. WE ARE STILL IN A "WAIT-AND-SEE MODE", WE ARE TAKING A CAUTIOUS APPROACH ON THAT.  Full Article

Attis To Collaborate With Novozymes To Provide Bio-Technology For Ethanol Production
Wednesday, 16 Jan 2019 

Jan 16 (Reuters) - Attis Industries Inc ::ATTIS ANNOUNCES COLLABORATION WITH NOVOZYMES TO PROVIDE BIO-TECHNOLOGY FOR ETHANOL PRODUCTION AT ITS BIOREFINERIES.ATTIS INDUSTRIES - NOVOZYMES HAS COMMITTED TO SUPPLYING ENZYMES REQUIRED BY CO TO CONVERT ITS PULP INTO SUGAR AT ALL OF ITS PLANNED BIOREFINERIES.  Full Article

Novozymes CFO Says Weaker Middle East Growth Is Expected To Continue
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - NOVOZYMES' CFO PRISCA HAVRANEK-KOSICEK TOLD REUTERS::NOVOZYMES CFO SAYS REASON FOR SALES GROWTH EXPECTED AT LOWER END OF RANGE IS LOWER GROWTH IN THE MIDDLE EAST.NOVOZYMES CFO SAYS LOWER MIDDLE EAST GROWTH IS EXPECTED TO CONTINUE IN THE FOURTH QUARTER.NOVOZYMES CFO SAYS HAD HOPED FOR HIGHER GROWTH IN HOUSEHOLD CARE SO FAR THIS YEAR.NOVOZYMES MAINTAINED ITS ORGANIC SALES GROWTH GUIDANCE OF 4-6 PCT FOR THIS YEAR BUT SAID IT WOULD LIKELY CLOSE THE YEAR TOWARD THE LOWER PART OF THE RANGE nASP0001N0.  Full Article

Novozymes delivers fresh profit warning, citing flood-hit ethanol market

COPENHAGEN, June 7 Shares in enzymes maker Novozymes slumped more than 8% on Friday after it cut its 2019 sales outlook for the second time in less than two months on the back of weak U.S. ethanol production after floods in the Midwest.